NAD+ at GWCIM is an intramuscular (IM) injection, not an IV infusion
10.1038/s41598-019-38956-2 109 ProbstL.MonneratS.VogtD
GLP 1 Receptor Agonist Cardiovascular Therapy Market Size, Share & Trends Analysis Distribution by Indication (Atherosclerotic Cardiovascular Disease, Heart Failure with Preserved Ejection Fraction, Neurological Indications, and Chronic Kidney Disease), Drug Class (GLP-1/GIP Dual Agonists, GLP-1 Mono-Agonists, and GLP-1/Amylin Combinations), End-user (Cardiologists, Hospital Systems, Primary Care Physicians, and Endocrinologists), and Segment Forecasts, 2026 to 2035 Glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide, liraglutide, and dulaglutide, are used in GLP-1 Receptor Agonist Cardiovascular Therapy to lower cardiovascular risk while treating metabolic diseases, especially type 2 diabetes and obesity
These results triggered the randomised, open-label ADOPTION trial program (comprising a Korean and a European trial with identical design) comparing the effects of adding 50 mg of opicapone or 100 mg of levodopa to subjects with a motor fluctuation history of less than 2 years and a maximum of 600 mg of levodopa per day
